Zegfrovy (sunvozertinib) received accelerated FDA approval for NSCLC patients with EGFR exon 20 insertion mutations post-platinum-based chemotherapy progression. The Oncomine Dx Express Test was ...
CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...
Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...
Rybrevant Faspro is a new under-the-skin (subcutaneous) injection form of the cancer medicine Rybrevant (amivantamab). The FDA has now approved it in combination with another medicine called ...
The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...
The APPLE trial began recruitment in November 2017 and ended in February 2020 (5). It was a randomised, open-label, non-comparative, multicentre, phase II study which enrolled treatment naïve patients ...
Thoracic medical oncologists and early drug development specialists at Memorial Sloan Kettering Cancer Center (MSK) continue to investigate new ways to improve outcomes for this patient population.
Disparities in lung cancer biomarker testing show barriers that delay diagnosis and treatment for lower-income patients, according to Sandip P. Patel, MD. Patients with lower socioeconomic status were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback